Development of antileishmanial lipid nanocomplexes

Pham, Thi-Minh-Hue; Gueutin, Claire; Chéron, Monique; Abreu, Sonia; Chaminade, Pierre; Loiseau, Philippe M.; Barratt, Gillian

doi:10.1016/j.biochi.2014.06.007

Cited by 19 publications

(23 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A JASCO J-810 CD Spectropolarimeter (Tokyo, JAPAN and Jasco Spectra Manager v2 software were used for the record these parameters. Cochleates obtained from Lipoid PSP70 containing 3×10 -5 M AmB (previously treated with 0.05M EDTA) were put in 1-cm path length quartz cuvettes (Pham et al, 2014). Suspensions of cochleates without AmB at the same lipid composition and concentration were used as blanks.…”

Section: Circular Dichroism and Uv-visible Spectroscopymentioning

confidence: 99%

“…Therefore, its stability in the different formulations was studied using simulated gastric fluid (SGF). Samples of AmB-loaded cochleate formulations and a control of AmB dissolved in DMSO were suspended in SGF (0.32% w/v pepsin and pH adjusted to 1.2) (Pham et al, 2014) at an AmB concentration of 10 µg/mL and incubated at 37°C under shaking at a speed of 75 rpm for 2 h. The suspension was immediately neutralised with the same volume of buffer (0.11M NaOH, 0.03M NaH 2 PO 4 and 0.05M EDTA) to pH 7, then 1 volume of MeOH was added followed by centrifugation in a VWR Galaxy Mini Centrifuge C1413 8 (2000 × g, 10 min). Finally, the supernatant was recovered to measure the AmB concentration by HPLC as described above.…”

Section: Stability Of Amb In Cochleates In Gastric Mediummentioning

confidence: 99%

See 1 more Smart Citation

Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipid

Lipa-Castro

Nicolas

Angelova

et al. 2021

International Journal of Pharmaceutics

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

Section: Circular Dichroism and Uv-visible Spectroscopymentioning

confidence: 99%

Section: Stability Of Amb In Cochleates In Gastric Mediummentioning

confidence: 99%

Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipid

Lipa-Castro

Nicolas

Angelova

et al. 2021

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Cochleates also differ from liposomes in that they lack an amphipathic core and exhibit water-free interior phases (Pham, Loiseau, & Barratt, 2013). In addition, cochleates are less susceptible to oxidation due to their nonaqueous structure and may protect the drug molecules from structural degradation after lyophilization (Pham et al, 2014). In addition, cochleates are less susceptible to oxidation due to their nonaqueous structure and may protect the drug molecules from structural degradation after lyophilization (Pham et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

“…This property confers several advantages to cochleates; for example, they release drugs slowly as the layers are gradually opened (Ramasamy, Khandasamy, Hinabindhu, & Kona, 2009). In addition, cochleates are less susceptible to oxidation due to their nonaqueous structure and may protect the drug molecules from structural degradation after lyophilization (Pham et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Çoban

Değim

Yılmaz³

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

The main challenges in treating cancer using chemotherapeutics are insufficient dose at the target site and the development of drug resistance, while higher doses can induce side effects by damaging nontarget tissues. Combinatorial drug therapy may overcome these limitations by permitting lower doses and more specific targeting, thereby mitigating drug resistance and nontarget side effects. Recent reports indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) have anticancer potential and can be used together with conventional chemotherapeutics to improve efficacy and safety. In the present study, imatinib mesylate and dexketoprofen trometamol were selected as model drugs to develop targeted surface-modified liposome and nanocochleate formulations for fibrosarcoma treatment. The physicochemical properties and in vitro efficacy of various formulations were evaluated by measurement of particle size distribution, polydispersity index, zeta potential, encapsulation efficiency, diffusion through Caco-2 cells, and toxicity in culture. Selected formulations were then evaluated in fibrosarcoma-bearing model mice by histopathological observations and tyrosine kinase receptor inhibition assays.The most effective formulation on the fibrosarcoma model was a PEGylated nanocochleate formulation. These findings provide a foundation for developing more effective formulations and chemotherapeutic strategies for the treatment of fibrosarcoma and other types of cancer.

show abstract

“…The release rate of MILT was slightly higher than that of AMB, probably because of the amphiphilic mechanisms of the former. Therefore, AMB-MILT-loaded nanocochleates revealed to be a promising oral delivery system for VL therapy (Pham et al, 2014). Jung and collaborators (2009) prepared the SLN which can entrap poor water-soluble drugs, AMB, with high drug entrapment efficiency by using solvent evaporation (SESE) and spontaneous emulsification low energy method.…”

Section: The Scope Of Lipid Nanoparticlementioning

confidence: 99%

Promising nanotherapy in treating leishmaniasis

Souza

Marins

Mathias

et al. 2018

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Leishmaniases are infectious diseases caused by an intracellular protozoan in humans by 20 different species of Leishmania among more than 53 species. There are at least twelve million cases of infections worldwide and three hundred and fifty million people are at risk in at least 98 developing countries in Africa, South-East Asia, and the Americas. Only Brazil presented high burden for both visceral leishmaniasis (VL) and cutaneous (CL). Chemotherapy is the main means of dealing with this infection. Nevertheless, only a few effective drugs are available, and each has a particular disadvantage; toxicity and long-term regimens compromise most chemotherapeutic options, which decreases patient compliance and adherence to the treatment and consequently the emergence of drug-resistant strains. Nano drug delivery systems (NanoDDS) can direct antileishmanial drug substances for intracellular localization in macrophage-rich organs such as bone marrow, liver, and spleen. This strategy can improve the therapeutic efficacy and reduce the toxic effects of several antileishmanial drug substances. This review is an effort to comprehensively compile recent findings, with the aim of advancing understanding of the importance of nanotechnology for treating leishmaniases.

show abstract

Development of antileishmanial lipid nanocomplexes

Cited by 19 publications

References 45 publications

Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipid

Cochleate formulations of Amphotericin b designed for oral administration using a naturally occurring phospholipid

Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma

Promising nanotherapy in treating leishmaniasis

Contact Info

Product

Resources

About